The diagnostic plot: A concept for identifying different states of iron deficiency and monitoring the response to epoetin therapy

Medical Oncology

Volumn 23, Issue 1, 2006, Pages 23-36

  Thomas, Christian ^a   Kirschbaum, Andreas ^b   Boehm, Dieter ^c   Thomas, Lothar ^d  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^c Klinik für Operative Intensivmedizin Krankenhaus   (Germany)

^d KRANKENHAUS NORDWEST   (Germany)

Author keywords

Anemia of chronic disease; Diagnostic plot; Epoetin therapy; Ferritin index; Iron deficiency; Soluble transferrin receptor

Indexed keywords

BIOLOGICAL MARKER; FERRITIN; HEMOGLOBIN; IRON; RECOMBINANT ERYTHROPOIETIN; TRANSFERRIN RECEPTOR;

ANEMIA; CELL DENSITY; CHRONIC DISEASE; DISEASE MARKER; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; ERYTHROCYTE; ERYTHROPOIESIS; HEMOGLOBIN DETERMINATION; HUMAN; INFECTION; INFLAMMATION; IRON BALANCE; IRON DEFICIENCY; IRON METABOLISM; IRON STORAGE; IRON THERAPY; MALIGNANT NEOPLASTIC DISEASE; PREDICTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RETICULOCYTE; REVIEW; STATISTICAL MODEL;

ANEMIA, IRON-DEFICIENCY; BIOLOGICAL MARKERS; EPOETIN ALFA; ERYTHROPOIESIS; HUMANS; IRON;

EID: 33646861415     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1385/MO:23:1:23     Document Type: Review

References (76)

1. Moliterno AR, Spivak JL. Anemia of cancer. Hematol Oncol Clin North Am 1996; 10: 345-363.
2. Van Belle SJB, Cocquyt V. Impact of haemoglobin levels on the outcome of cancers treated with chemotherapy. Crit Rev Oncol/Haematol 2003; 47: 1-11.
3. Engert A. Recombinant human erythropoietin as an alternative to blood transfusion in cancer-related anemia. DMMA 2000; 5: 259-272.
4. Cazzola M, et al. Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin's lymphoma: dose finding and identification of predictors of response. Blood 1995; 86: 4446-4453.
5. Österborg A, et al. Recombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin's lymphoma - a randomized multicenter study. Blood 1996; 87: 2675-2682.
6. Cazzola M, Mercuriali F, Brugnara C. Use of recombinant human erythropoietin outside the setting of uremia. Blood 1997; 89: 4248-4267.
7. Nowrousian MR. Recombinant human erythropoietin in the treatment of cancer-related or chemotherapy induced anaemia in patients with solid tumours. Med Oncol 1998; 15 (Suppl 1): S19-S28.
8. Oberhoff C, et al. Effekt von rekombinantem humanen Erythropoetin auf den Transfusionsbedarf und die Hämoglobinkonzentration bei Patienten mit soliden Tumoren und chemotherapie-induzierter Anämie. Tumordiagn u Ther 2000; 21: 15-25.
9. Österborg A, et al. Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, Epoetin beta, in hematologic malignancies. J Clin Oncol 2002; 20: 2486-2494.
10. Vansteenkiste J, et al. Double-blind, placebo-controlled, randomized phase III trial of Darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 2002; 94: 1211-1220.
11. Hedenus M, et al. Efficacy and safety of darbepoetin alpha in anemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study. Br J Haematol 2003; 122: 394-403.
12. Cazzola M, Beguin Y, Kloczo J, Spicka I, Coiffier B. Once-weekly epoetin beta is highly effective in treating anaemic patients with lymphoproliferative malignancy and detective endogenous erythropoietin production. Br J Haematol 2003; 122: 386-393.
13. Rizzo JD, et al. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. Blood 2002; 100: 2303-2319.
14. Bokemeyer C, et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer. Eur J Cancer 2004; 40: 2201-2216.
15. Papadaki HA, Kritikos HD, Valatas V, et al. Anemia of chronic disease in rheumatoid arthritis is associated with increased apoptosis of bone marrow erythroid cells; improvement following anti-tumor necrosis factor-α antibody therapy. Blood 2002; 100: 474-482.
16. Tilg H, Ulmer H, Kaser A, Weiss G. Role of IL-10 for induction of anemia during inflammation. J Immunol 2002; 169: 2204-2209.
17. Ludwiczek S, Aigner E, Theurl I, Weiss G. Cytokine-mediated regulation of iron transport in human monocytic cells. Bood 2003; 101: 4148-4154.
18. Alvarez-Hernandez X, Liceaga J, McKay IC, Brock JH. Induction of hypoferremia and modulation of macrophage iron metabolism by tumor necrosis factor. Lab Invest 1989; 61: 319-322.
19. Eschbach JW. Anemia management in chronic kidney disease: role of factors affecting epoetin responsiveness. J Am Soc Nephrol 2002; 13: 1412-1414.
20. Steenvinkel P. The role of inflammation in the anaemia of end-stage renal disease. Nephrol Dial Transplant 2001; 16 (Suppl 7): 36-40.
21. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med 2005; 352: 1011-1023.
22. Macdougall IC, Cooper A. The inflammatory response and epoetin sensitivity. Nephrol Dial Transplant 2002; 17 (Suppl 1): 48-52.
23. Means RT Jr, Krantz SB. Progress in understanding the pathogenesis of anemia of chronic disease. Blood 1992; 80: 1639-1647.
24. Cavill I, Macdougall IC. Functional iron deficiency. Blood 1993; 82: 1377.
25. Andrews NC. Anemia of inflammation: the cytokine-hepcidin link. J Clin Invest 2004; 113: 1251-1253.
26. Cavill I. Erythropoiesis and iron. Best Prac Res Clin Haematol 2002; 15: 399-409.
27. Thomas C, Thomas L. Anemia of chronic disease: pathophysiology and laboratory diagnosis. Lab Hematol 2005; 11: 14-23.
28. Bainton DF, Finch CA. The diagnosis of iron deficiency anemia. Am J Med 1964; 37: 62-70.
29. Baynes RD. Assessment of iron status. Clin Biochem 1996; 29: 209-215.
30. Trey JE, Kushner I. The acute phase response and the hematopoietic system: the role of cytokines. CRC Oncol/Hematol 1995; 21: 1-18.
31. Skikne BS. Circulating transferrin receptor assay - coming of age. Clin Chem 1998; 44: 7-9.
32. Beguin Y. Soluble transferrin receptor for the evaluation of erythropoiesis and iron status. Clin Chim Acta 2003; 329: 9-22.
33. Worwood M. Serum transferrin receptor assays and their application. Ann Clin Biochem 2002; 39: 221-230.
34. Baynes RD, Skikne BS, Cook JD. Circulating transferrin receptors and assessment of iron status. J Nutr Biochem 1994; 5: 322-330.
35. Punnonen K, Irjala K, Rajarnäki A. Serum transferrin receptor and its ratio to serum ferritin in the diagnosis of iron deficiency. Blood 1997; 89: 1052-1057.
36. Suominen P, Punnonen K, Rajarnäki A, Irjala K. Serum trasnsferrin receptor and transferrin receptor-ferritin index identify healthy subjects with subclinical iron deficits. Blood 1998; 92: 2934-2939.
37. Malope BI, MacPhail AP, Alberts M, Hiss DC. The ratio of serum transferrin receptor and serum ferritin in the diagnosis of iron status. Br J Haematol 2001; 115: 84-89.
38. Lee EJO, Park YJ, Lee HK, Kim BK. Soluble transferrin receptor (sTfR), ferritin and sTfR/log ferritin index in anemic patients with non hematologic malignancy of chronic inflammation. Clin Chem 2002; 48: 1118-1121.
39. Rimon E, et al. Diagnosis of iron deficiency anemia in the elderly by transferrin receptor-ferritin index. Arch Intern Med 2002; 162: 445-449.
40. Cermak J, Brabec V. Transferrin receptor-ferritin index: a useful parameter in differential diagnosis of iron deficiency and hyperplastic erythropoiesis. Eur J Haematol 1998; 61: 210-212.
41. Torti FM, Torti SV. Regulation of ferritin genes and protein. Blood 2002; 99: 3505-3516.
42. Krantz SB. Pathogenesis and treatment of the anemia of chronic disease. Am J Med Sci 1994; 307: 353-359.
43. Kalantar-Zadeh K, Rodriguez RA, Humphreys MH. Association between serum ferritin and measures of inflammation, nutrition and iron in haemodialysis patients. Nephrol Dial Transplant 2004; 19: 141-149.
44. Skikne BS, Flowers CH, Cook JD. Serum transferrin receptor: a quantitative measure of tissue iron deficiency. Blood 1990; 75: 1870-1876.
45. Mast AE, Blinder MD, Gronowski AM, Chumley C, Scott MG. Clinical utility of the soluble transferrin receptor and comparison with serum ferritin in several populations. Clin Chem 1998; 44: 532-541.
46. Thomas C, Thomas L. Biochemical markers and hematologic indices in the diagnosis of functional iron deficiency. Clin Chem 2002; 48: 1066-1076.
47. Ahluwalia N, Skikne BS, Savin V, Chonko A. Markers of masked iron deficiency and effectiveness of erythropoietin therapy in chronic renal failure. Am J Kidney Dis 1997; 30: 532-541.
48. Brugnara C. Reticulocyte cellular indices: a new approach in the diagnosis of anemias and monitoring of erythropoietic function. Crit Rev Clin Lab Sci 2000; 97: 93-130.
49. McDougal IC, et al. Detection of functional iron deficiency during erythropoietin treatment: a new approach. Br Med J 1992; 304: 225-226.
50. McDougal IC. What is the most appropriate strategy to monitor functional iron deficiency in the dialysed patient on r-HuEPO therapy? Merits of percentage hypochromic red cells as a marker of functional iron deficiency. Nephrol Dial Transplant 1998; 13: 847-849.
51. Bovy C, et al. Factors determining the percentage of hypochromic red blood cells in hemodialysis patients. Kidney Int 1999; 56: 1113-1119.
52. European best practice guidelines for the management of anemia in patients with chronic renal failure. Nephrol Dial Transplant 1999; 14 (Suppl 5): 1-50.
53. Briggs C, Rogers R, Thompson B, Machin SJ. New red cell parameters on the Sysmex XE-2100 as potential markers of functional iron deficiency. Infus Ther Transfus Med 2001; 28: 256-262.
54. Buttarello M, Temporin V, Ceravolo R, Farina G, Bulian P. The new reticulocyte parameter (RET-Y) of the Sysmex XE 2100. Am J Clin Pathol 2004; 121: 489-495.
55. Franck S, Linssen J, Messinger M, Thomas L. Clinical utility of the RET-Y in iron-restricted erythropoiesis. Clin Chem 2004; 50: 1240-1242.
56. Brugnara C, Zurakowski D, DiCanzio J, Boyd T, Platt O. Reticulocyte hemoglobin content to diagnose iron deficiency in children. JAMA 1999; 281: 2225-2230.
57. Fishbane S, Shapiro W, Dutka P, Valenzuela OF, Faulbert J. A randomized trial of iron deficiency testing strategies in hemodialysis patients. Kidney Int 2001; 60: 2406-2411.
58. Mittman N, et al. Reticulocyte hemoglobin content predicts functional iron deficiency in hemodialysis patients receiving rHuEPO. Am J Kidney Dis 1997; 30: 912-922.
59. Schaefer RM, Schaefer L. Hypochromic red blood cells and reticulocytes. Kidney Int 1999; 55 (Suppl 5): S44-S48.
60. Dati F, et al. Consensus of a group of professional societies and diagnostic companies on guidelines for interim reference ranges for 14 proteins based on the standardization against the IFCC/BCR/CAP reference material (CRM 470). Eur J Clin Chem Clin Biochem 1996; 34: 517-520.
61. d'Onofrio G, Zini G, Ricerca BM, Mancini S, Mango G. Automated measurement of red blood cell microcytosis and hypochromia in iron deficiency and β thalassemia trait. Arch Pathol Lab Med 1992; 116: 84-89.
62. NKF-K/DOQI Clinical Practice Guidelines For Anemia Of Chronic Kidney Disease: Update 2000. Am J Kidney Dis 2001; 37 (Suppl 1): S182-S238.
63. Tarnq DC, Huang TP. Determinants of circulating soluble transferrin receptor level in chronic haemodialysis patients. Nephrol Dial Transplant 2002; 17: 1063-1069.
64. Sunder-Plassmann G, Hörl WH. Erythropoietin and iron. Clin Nephrol 1997; 47: 141-157.
65. Nissenson AR, Charytan C. Controversies in iron management. Kidney Int 2003; 87: (Suppl 87): S64-S71.
66. Auerbach M, et al. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial. J Clin Oncol 2004; 22: 1301-1307.
67. Henry DH, et al. Intravenous ferric gluconate (FG) for increasing response to epoetin (EPO) in patients with anemia of cancer chemotherapy - results of a multicenter, randomized trial. Blood 2004; 104: ASH Meeting, Abstract 3696.
68. Cazzola M, et al. Prediction of response to recombinant human erythropoietin (r-HuEPO) in anemia of malignancy. Haematologica 1996; 81: 434-441.
69. Ludwig H, et al. Prediction of response to erythropoietin treatment in chronic anemia of cancer. Blood 1994; 84: 1056-1063.
70. Henry D, Abels R, Larholt K. Prediction of response to recombinant human erythropoietin (r-HuEPO/epoietin α) therapy in cancer patients. Blood 1995; 85: 1876-1878.
71. Kaneko Y, Miyazaki S, Hirasawa Y, Gejyo F, Suzuki M. Transferrin saturation versus reticulocyte hemoglobin content for iron deficiency in Japanese hemodialysis patients. Kidney Int 2003; 63: 1086-1093.
72. Flowers CH, Skikne BS, Covell AM, Cook JD. The clinical measurements of serum transferrin receptor. J Lab Clin Med 1989; 119: 385-390.
73. Chiang WC, Tsai TJ, Chen YM, Lin SL, Hsieh BS. Serum soluble transferrin receptor reflects erythropoiesis but not iron availability in erythropoietin-treated chronic hemodialysis patients. Clin Nephrol 2002; 58: 363-369.
74. Deira J, et al. Soluble transferrin receptor levels in haemodialysis patients. Nephrol Dial Transplant 2003; 18: 1945-1946.
75. Katodritou E, et al. Prediction of response to r-HuEPO in anemic multiple myeloma patients using a combination of sTfR-F index and hypochromic erythrocytes. Clin Chem 2005; 50: in press.
76. Brugnara C, et al. Effect of subcutaneous recombinant human erythropoietin in normal subjects: development of decreased reticulocyte hemoglobin content and iron-deficient erythropoiesis. J Lab Clin Med 1994; 123: 660-667.